Evidence map›Paper›PMID 12584318›Full record

ArticleJournal of virology2003

N-linked glycosylation and sequence changes in a critical negative control region of the ASCT1 and ASCT2 neutral amino acid transporters determine their retroviral receptor functions.

Mariana Marin, Dimitri Lavillette, Sean M Kelly, David Kabat

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 112 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Receptor usage of Syncytin-1: ASCT2, but not ASCT1, is a functional receptor and effector of cell fusion in the human placenta.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Human gene therapy · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mariana MarinDepartment of Biochemistry and Molecular Biology, Oregon Health & Science University, Portland, Oregon 97201-3098, USA.
Dimitri Lavillette
Sean M Kelly
David Kabat
Oregon Health & Science University · US

Funding

RETROVIRAL RECEPTORS--HIV-1/AIDSR01CA067358 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI KABAT, DAVID · 1995 to 2014
$4.4M
LEUKEMOGENIC RETROVIRAL GLYCOPROTEIN: GP55-GP70SR01CA025810 · NCI · OREGON HEALTH AND SCIENCE UNIVERSITY · PI KABAT, DAVID · 1985 to 2001
$414k
Control of HIV-1 Entry Rates by Antibodies and CCR5 RegionsR56CA067358 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI KABAT, DAVID · 2009 to 2009
$197k
NCI NIH HHS CA25810NCI NIH HHS CA67358NCI NIH HHS R01 CA067358NCI NIH HHS R56 CA067358
6 · The paper itself

Abstract

A widely dispersed interference group of retroviruses that includes the feline endogenous virus (RD114), baboon endogenous virus (BaEV), human endogenous virus type W (HERV-W), and type D primate retroviruses uses the human Na(+)-dependent neutral amino acid transporter type 2 (hASCT2; gene name, SLC1A5) as a common cell surface receptor. Although hamster cells are fully resistant to these viruses and murine cells are susceptible only to BaEV and HERV-W pseudotype viruses, these rodent cells both become highly susceptible to all of the viruses after treatment with tunicamycin, an inhibitor of protein N-linked glycosylation. A partial explanation for these results was recently provided by findings that the orthologous murine transporter mASCT2 is inactive as a viral receptor, that a related (ca. 55% identity) murine paralog (mASCT1; gene name, SLC1A4) mediates infections specifically of BaEV and HERV-W, and that N-deglycosylation of mASCT1 activates it as a receptor for all viruses of this interference group. Because the only two N-linked oligosaccharides in mASCT1 occur in the carboxyl-terminal region of extracellular loop 2 (ECL2), it was inferred that this region contributes in an inhibitory manner to infections by RD114 and type D primate viruses. To directly and more thoroughly investigate the receptor active sites, we constructed and analyzed a series of hASCT2/mASCT2 chimeras and site-directed mutants. Our results suggest that a hypervariable sequence of 21 amino acids in the carboxyl-terminal portion of ECL2 plays a critical role in determining the receptor properties of ASCT2 proteins for all viruses in this interference group. In addition, we analyzed the tunicamycin-dependent viral susceptibility of hamster cells. In contrast to mASCT1, which contains two N-linked oligosaccharides that partially restrict viral infections, hamster ASCT1 contains an additional N-linked oligosaccharide clustered close to the others in the carboxyl-terminal region of ECL2. Removal of this N-linked oligosaccharide by mutagenesis enabled hamster ASCT1 to function as a receptor for all viruses of this interference group. These results strongly suggest that combinations of amino acid sequence changes and N-linked oligosaccharides in a critical carboxyl-terminal region of ECL2 control retroviral utilization of both the ASCT1 and ASCT2 receptors.

Indexed as

Gene Expression RegulationAmino Acid SequenceAmino Acid SubstitutionAmino Acid Transport System ASCAnimalsAntiviral AgentsCell LineCHO CellsCricetinaeGlycosylationHumansMinor Histocompatibility AntigensMolecular Sequence DataMutagenesis, Site-DirectedReceptors, VirusRetroviridaeAmino Acid Transport System ASCAntiviral AgentsMinor Histocompatibility AntigensReceptors, VirusSLC1A4 protein, humanSLC1A5 protein, humanTunicamycin

Identifiers

PMID12584318
PMCPMC149750
OpenAlexW2110632348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.